AI and Precision Medicine: How Artificial Intelligence Is Transforming Personalized Healthcare

By

Artificial intelligence (AI) and precision medicine are converging to create a new model of healthcare—one that aims to understand the individual patient rather than treating everyone according to an average.

Modern medicine is generating an extraordinary amount of biological and clinical information. Genomic sequencing, electronic health records, medical imaging, digital pathology, laboratory testing, wearable devices, continuous glucose monitoring, microbiome analysis and increasingly sophisticated molecular measurements can all contribute to a patient's health profile.

The challenge is no longer simply collecting data. It is turning enormous amounts of heterogeneous data into clinically useful decisions.

That is where artificial intelligence may become particularly important.

Precision medicine considers differences among patients—including genes, environment and lifestyle—when guiding prevention, diagnosis and treatment. AI can potentially help clinicians integrate these multiple dimensions at a scale that would be difficult to achieve manually.

What Is Precision Medicine?

Precision medicine is an approach to healthcare that takes individual variation into account when preventing, diagnosing or treating disease.

Instead of asking only:

"What treatment works best for the average patient?"

precision medicine asks:

"Which treatment, prevention strategy or monitoring approach is most appropriate for this particular patient, given what we know about their biology and circumstances?"

The distinction is important. Precision medicine does not necessarily mean creating a completely unique treatment for every individual. Rather, it often involves identifying clinically meaningful patient subgroups that differ in disease risk, biology, prognosis or treatment response.

Wearable technology market size was $92.90 billion in 2025 and is projected to reach $229.97 billion by 2033, growing at a CAGR of 12.1% from 2026 to 2033. (Grand View Research)

Depending on the disease, relevant information can include:

  • Genetic variants
  • Whole-genome or exome sequencing
  • RNA and gene-expression patterns
  • Proteomics and metabolomics
  • Medical imaging
  • Digital pathology
  • Clinical history
  • Laboratory biomarkers
  • Medications and treatment history
  • Environmental exposures
  • Diet and lifestyle
  • Wearable and continuous-monitoring data

The objective is to move medicine toward better-matched decisions rather than simply more data.

What Role Does AI Play in Precision Medicine?

AI is particularly suited to precision medicine because the relevant information is often too complex, high-dimensional and interconnected for conventional analysis.

Machine-learning systems can identify patterns in large datasets, while newer AI systems can help integrate information from different data types.

For example, an AI-assisted precision medicine system could potentially combine:

  • A patient's genomic profile
  • Tumor sequencing
  • Pathology images
  • Radiology scans
  • Blood biomarkers
  • Electronic health records
  • Previous treatment responses
  • Medication history
  • Comorbidities
  • Age and other clinical characteristics

The result is potentially a more comprehensive representation of the patient's disease than any individual data source can provide.

Research in precision oncology illustrates this convergence particularly well. Recent reviews describe AI/ML applications across multi-omics, spatial pathology, radiomics, electronic health records, biomarker discovery and treatment selection.

The Data Layer of Precision Medicine

AI is only as useful as the data and clinical framework surrounding it.

Precision medicine increasingly depends on several layers of information.

1. Genomic data

DNA sequencing can identify inherited or acquired genetic variants that may influence disease susceptibility or treatment response.

2. Transcriptomic data

RNA and gene-expression measurements provide information about which genes are active and how biological systems are functioning.

3. Proteomic data

Proteomics measures proteins and their abundance or modification, providing another layer of information about biological activity.

4. Metabolomic data

Metabolomics examines small molecules involved in metabolism and can provide clues about physiological state and disease biology.

5. Imaging

Radiology and pathology generate enormous amounts of visual information. AI can analyze patterns that may be difficult or time-consuming for humans to quantify consistently.

6. Clinical data

Age, symptoms, diagnoses, medications, laboratory values, previous treatments and outcomes remain essential.

7. Lifestyle and environmental information

Diet, physical activity, sleep, environmental exposures and other behavioral factors can influence disease risk and treatment outcomes.

The fundamental opportunity is therefore not simply AI + genomics. It is the integration of multiple biological, clinical and environmental layers.

AI and Genomics: From Sequence to Meaning

Genomic sequencing has made it possible to measure enormous quantities of genetic information. But identifying a genetic variant is not the same as understanding its clinical significance.

AI can potentially assist with:

  • Variant classification
  • Prediction of functional effects
  • Identification of disease-associated patterns
  • Genotype-phenotype associations
  • Analysis of gene-expression signatures
  • Identification of molecular subtypes
  • Prediction of treatment response

This distinction between measurement and interpretation is crucial.

A sequencing test may generate thousands or millions of observations. The clinical problem is determining which observations matter.

AI may become an important layer between raw biological data and clinical interpretation—but clinical validation remains essential.

AI and Precision Oncology

Cancer may be one of the clearest examples of why AI and precision medicine belong together.

Cancer is not a single disease. Even tumors with the same anatomical diagnosis can have substantially different molecular characteristics, immune environments, evolutionary trajectories and treatment responses.

Modern precision oncology therefore increasingly considers:

  • Somatic mutations
  • Germline variants
  • Gene-expression profiles
  • Tumor mutational burden
  • Microsatellite instability
  • DNA repair pathways
  • Immune-cell composition
  • Pathology features
  • Radiographic characteristics
  • Treatment history
  • Mechanisms of resistance

AI can potentially integrate these variables to identify clinically relevant patterns.

A 2025 review in npj Digital Medicine described the convergence of AI/ML with multi-omics, spatial pathology, radiomics and other data modalities in precision oncology, while emphasizing substantial challenges involving data quality, generalizability, clinical workflows and implementation.

AI-assisted cancer diagnosis

AI systems can analyze pathology slides and medical images to assist with cancer detection, classification and prognostic assessment.

Research has also explored whether image-derived features can predict molecular characteristics and treatment response.

AI-assisted biomarker discovery

One of the most important applications may be identifying biomarkers that distinguish patients who are more or less likely to respond to a particular treatment.

This is important because many candidate biomarkers identified in research have difficulty demonstrating sufficient reproducibility and robustness for routine clinical use. Computational approaches may help search for more complex combinations of predictors.

AI-assisted treatment selection

Instead of relying exclusively on a single biomarker, future systems may evaluate combinations of molecular, pathological, imaging and clinical features.

The objective is not simply to identify what mutation is present, but to estimate:

"Given this patient's complete disease profile, which available treatment is most likely to provide meaningful benefit with acceptable risk?"

Can AI Predict Which Treatment Will Work?

This is one of the most ambitious goals of precision medicine.

Traditional clinical medicine often estimates treatment benefit using population-level evidence. Precision medicine attempts to refine that estimate for individual patients or biologically meaningful subgroups.

AI may help by analyzing relationships between:

  • Molecular characteristics
  • Clinical features
  • Previous treatment exposure
  • Biomarkers
  • Imaging
  • Pathology
  • Drug-response datasets
  • Longitudinal patient outcomes

In oncology, computational approaches are increasingly being investigated for predictive biomarker discovery and treatment-response prediction.

However, an important distinction must be maintained:

A model that predicts treatment response is not automatically proof that changing treatment according to the model improves survival or quality of life.

That requires prospective clinical validation.

AI, Drug Discovery and Drug Repurposing

Precision medicine does not stop at selecting existing therapies. AI may also influence how therapies are discovered.

Potential applications include:

  • Target identification
  • Drug-target interaction prediction
  • Virtual screening
  • Molecular structure optimization
  • Biomarker discovery
  • Patient-selection strategies
  • Combination-treatment modeling
  • Prediction of drug resistance
  • Drug repurposing

In cancer research, computational approaches are also being explored to predict drug combinations and treatment synergies.

This could eventually support a more integrated development model:

Target → Biomarker → Patient subgroup → Treatment → Response → Resistance → Next treatment.

That feedback loop is central to the concept of adaptive precision medicine.

Digital Twins and Virtual Patients

One of the more futuristic applications of AI in precision medicine is the concept of a digital twin or computational representation of an individual patient.

In principle, such a system could combine genomic, clinical, imaging and physiological information to model possible disease trajectories or treatment responses.

Researchers are already investigating synthetic data and digital-twin concepts in precision oncology, including their potential role in clinical-trial design.

However, digital twins should not be confused with a fully accurate virtual copy of a human being.

Human biology is dynamic, incompletely measured and influenced by factors that models may not capture.

The realistic near-term goal is more modest: decision-support models that simulate plausible scenarios and help researchers or clinicians compare options.

AI and Predictive Prevention

Precision medicine may ultimately have its greatest impact before disease becomes clinically obvious.

AI could analyze combinations of:

  • Genetic risk
  • Family history
  • Laboratory biomarkers
  • Imaging
  • Metabolic measurements
  • Blood pressure
  • Glucose patterns
  • Physical activity
  • Sleep
  • Environmental exposures

This could allow healthcare systems to identify people at elevated risk and intervene earlier.

The concept is consistent with the broader goal of precision medicine: identifying individual differences in disease susceptibility and using that information to guide prevention and treatment.

But predictive risk is not destiny.

A genetic or AI-derived risk score should be understood as probabilistic information, not a prediction that a particular person will definitely develop a disease.

AI and Pharmacogenomics

Pharmacogenomics examines how genetic variation can influence responses to medications.

Different patients can metabolize or respond to the same drug differently. Genetic information can sometimes help identify patients for whom a particular medication, dose or treatment strategy may be more appropriate.

NIH identifies pharmacogenomics as an important component of precision medicine, with the broader objective of moving toward the right drug, at the right dose, at the right time, for the right patient.

AI could expand this concept by integrating pharmacogenomic information with:

  • Kidney and liver function
  • Age
  • Drug interactions
  • Comorbidities
  • Previous treatment response
  • Other biomarkers

This moves pharmacogenomics from a single genetic test toward a broader treatment-response prediction system.

The Rise of Multimodal Medicine

The most important development may be the transition from single-data-point medicine to multimodal medicine.

Imagine a patient represented not by one test but by a multidimensional data profile:

DNA → inherited risk and mutations

RNA → gene activity

Proteins → biological activity

Metabolites → metabolic state

Pathology → tissue architecture

Imaging → anatomy and disease phenotype

Clinical data → symptoms, history and treatment

Wearables → continuous physiological information

Environment → exposures and context

AI can potentially act as the integration layer connecting these otherwise fragmented datasets.

This is particularly important because complex diseases are rarely caused by one variable.

Cancer, cardiovascular disease, diabetes, neurodegeneration and autoimmune disease are systems-level problems.

Precision medicine therefore increasingly requires systems-level analysis.

Why AI Is Not Yet a Medical Oracle

The excitement surrounding AI should not obscure its limitations.

1. Garbage in, garbage out

Biased, incomplete or poorly labeled data can produce unreliable models.

2. Correlation is not causation

AI can identify patterns without establishing that one factor causes another.

3. Generalizability is difficult

A model trained in one hospital, population or healthcare system may perform differently elsewhere.

4. Clinical validation matters

High performance on a retrospective dataset does not necessarily translate into better patient outcomes.

5. Explainability remains important

Clinicians and patients may need to understand why a model is recommending a particular action, especially when the decision involves substantial risk.

6. Data privacy is critical

Genomic and clinical data are highly sensitive. Precision medicine therefore requires strong governance around data security, consent and appropriate use.

7. AI can amplify existing healthcare inequalities

If training datasets underrepresent certain populations, AI systems may perform less reliably for those groups.

8. Human judgment remains essential

Medicine involves uncertainty, patient preferences, ethics, competing risks and contextual judgment that cannot simply be reduced to a prediction score.

Recent reviews emphasize that technical, data-quality, generalizability, workflow and reimbursement barriers remain important obstacles to implementing AI-enabled precision medicine.

AI Should Augment Doctors—Not Replace Them

The most credible vision of AI-powered precision medicine is not a machine replacing the physician.

It is a human-AI clinical partnership.

AI can potentially:

  • Process millions of data points
  • Identify patterns
  • Rank possible diagnoses
  • Highlight biomarkers
  • Search medical literature
  • Estimate risks
  • Model treatment options
  • Monitor longitudinal changes

The clinician contributes:

  • Clinical judgment
  • Context
  • Ethical reasoning
  • Patient preferences
  • Communication
  • Experience
  • Responsibility for the final clinical decision

Recent commentary in Nature Reviews Clinical Oncology similarly argues for synergy between AI capabilities and human clinical expertise rather than simple replacement of clinicians.

The Future of AI-Powered Precision Medicine

The next stage of medicine may involve a continuous learning loop.

Measure → collect biological and clinical data

↓

Interpret → AI integrates multimodal information

↓

Predict → estimate risk and treatment response

↓

Intervene → select prevention or treatment strategies

↓

Monitor → measure response continuously

↓

Learn → update the patient's model

↓

Adapt → modify the strategy as biology changes

This is fundamentally different from the traditional model of diagnosing a disease once and applying a relatively static treatment plan.

It points toward adaptive, longitudinal and data-driven medicine.

From precision medicine to dynamic precision medicine

Patients are not static.

Tumors evolve. Metabolism changes. Immune responses change. Drugs alter physiology. Lifestyle changes. Aging changes biological systems.

Therefore, the most advanced form of precision medicine may not be:

"What treatment is best for this patient?"

but:

"What is the best decision for this patient right now, and how should that decision change as new information arrives?"

AI could make this type of continuous decision support increasingly feasible.

AI + Precision Medicine + Systems Biology

The convergence becomes even more powerful when precision medicine is combined with systems biology.

Rather than viewing disease as a single defective gene or isolated pathway, systems biology examines interacting networks.

For example, a complex disease may involve interactions among:

  • Genetics
  • Epigenetics
  • Metabolism
  • Immune signaling
  • Inflammation
  • Microbiome
  • Hormonal signaling
  • Environmental exposures
  • Behavior

AI is potentially valuable because these networks generate patterns that are difficult to analyze using conventional one-variable-at-a-time approaches.

This could support a broader model of systems precision medicine: understanding the patient as a dynamic biological system rather than a collection of isolated laboratory values.

Key Takeaways

  • Precision medicine uses individual differences in biology, environment and lifestyle to improve prevention, diagnosis and treatment.
  • AI provides an analytical engine capable of integrating large, complex datasets.
  • Genomics is only one layer; future precision medicine will increasingly combine genomic, transcriptomic, proteomic, metabolic, imaging and clinical information.
  • Precision oncology is a leading application because cancer biology is highly heterogeneous and dynamic.
  • AI may improve biomarker discovery and treatment-response prediction, but predictions still require rigorous clinical validation.
  • AI may accelerate drug discovery and repurposing by identifying biological relationships and potential treatment combinations.
  • Digital twins and computational patient models are promising but remain developing technologies rather than perfect virtual replicas of patients.
  • AI should augment clinicians rather than be treated as an autonomous replacement for medical judgment.
  • The biggest opportunity may be multimodal and longitudinal medicine, where biological information is continuously integrated over time.
  • The future is likely to be adaptive: measure, predict, intervene, monitor and continuously update.

Frequently Asked Questions

What is AI in precision medicine?

AI in precision medicine refers to the use of artificial intelligence and machine-learning methods to analyze individual-level biological, clinical and environmental information to support more precise prevention, diagnosis, prognosis and treatment decisions.

How does AI improve precision medicine?

AI can identify patterns across large and complex datasets, potentially helping clinicians interpret genomic information, discover biomarkers, predict treatment response, analyze medical images and integrate multiple sources of patient information.

Is precision medicine the same as personalized medicine?

The terms are often used interchangeably, but NIH generally prefers precision medicine. Importantly, precision medicine does not necessarily mean designing a completely unique treatment for every individual; it can involve identifying groups of patients who share biologically meaningful characteristics.

Will AI replace doctors?

That is not the most useful model for clinical AI. AI is particularly strong at computation, pattern recognition and data integration, while clinicians provide contextual judgment, communication, ethics and responsibility for patient care. The emerging model is therefore better described as AI-augmented medicine.

Can AI predict which cancer treatment will work?

AI research is increasingly investigating treatment-response prediction and predictive biomarker discovery. However, an algorithmic prediction is not automatically evidence that using that prediction to select therapy improves patient outcomes. Prospective clinical validation remains essential.

What is multimodal AI in medicine?

Multimodal AI refers to systems capable of integrating different types of information—for example, text, medical images, pathology, genomic data, laboratory results and clinical records—rather than analyzing only one data type.

What are the biggest barriers to AI precision medicine?

Major challenges include data quality, bias, privacy, interoperability, model validation, generalizability, explainability, clinical workflow integration, regulation and demonstrating that AI actually improves patient outcomes.

Conclusion: The Next Era of Medicine May Be Predictive, Adaptive and Individualized

The promise of precision medicine has always been to move beyond the concept of the average patient.

AI may provide the computational infrastructure required to make that vision increasingly practical.

Genomics can reveal biological predisposition. Imaging can reveal phenotype. Pathology can reveal tissue architecture. Laboratory testing can reveal physiology. Wearables can provide continuous measurements. Clinical records provide context.

AI can potentially connect these layers.

The result could be a healthcare model that is more predictive, more adaptive and more individualized.

But the future should not be defined by algorithms alone. The strongest model is likely to be AI + human expertise + high-quality data + rigorous clinical evidence + patient preferences.

That combination—not artificial intelligence by itself—is what could turn precision medicine from an ambitious concept into a practical foundation for next-generation healthcare.

Important: This article is an educational overview of AI and precision medicine. AI-generated predictions, genomic findings and risk scores should not be interpreted as a diagnosis or individualized medical recommendation. Clinical decisions should be made with qualified healthcare professionals using validated evidence and appropriate patient-specific information.

Selected References and Further Reading

  • NIH — Precision medicine definitions and overview.
  • Fountzilas E, et al. Convergence of evolving artificial intelligence and machine learning techniques in precision oncology. npj Digital Medicine. 2025.
  • Reardon B, Culhane AC, Van Allen EM. Convergence of machine learning and genomics for precision oncology. Nature Reviews Cancer. 2026.
  • Discovery of predictive biomarkers for cancer therapy through computational approaches. Nature Reviews Clinical Oncology. 2026.
  • Zhu E, et al. Progress and challenges of artificial intelligence in lung cancer clinical translation. npj Precision Oncology. 2025.
  • U.S. FDA. Considerations for the Use of Artificial Intelligence To Support Regulatory Decision-Making for Drug and Biological Products. 2025 draft guidance.

Comments

Post a Comment

Popular posts from this blog

Ivermectin for Parkinson’s and Dementia: Analyzing the Neuroprotective Molecular Evidence and Clinical Case Reports (2026)

By
Image
Scientific Review & Regulatory Audit by the Clinical Editorial Team The therapeutic paradigm for progressive neurodegenerative disorders like Parkinson’s disease (PD) and various forms of dementia faces a critical bottleneck. Standard pharmacology, primarily anchored by levodopa (L-DOPA) for Parkinson’s and acetylcholinesterase inhibitors for dementia, remains strictly symptomatic. These options frequently suffer from diminishing efficacy and significant side-effect profiles like L-DOPA-induced dyskinesia over long-term use. Consequently, the pharmaceutical community has focused heavily on drug repurposing—identifying established, safety-vetted compounds capable of crossing pathways to modify disease progression. An unexpected frontline candidate emerging in this space is ivermectin. Traditionally classified as a broad-spectrum antiparasitic agent, a surge of preclinical studies between 2020 and 2024 has unveiled its complex, multi-targeted pharmacodynamics within the mam...
Read more

NAC vs NAD vs NR vs NMN vs Niacin: What Are the Differences?

By
Image
By the One Day MD Editorial Team  |  Originally published September 2020  |  Last updated and medically fact-checked: July 26, 2026 NAD, NAD+, NADH, NR, NMN, niacin, niacinamide, and NAC — these overlapping names cause constant confusion, and understandably so. Some are simply different names for the same molecule. Others are metabolic precursors that your body converts, step by step, into NAD+. One of them, NAC, isn't related to NAD+ metabolism at all. This guide breaks down what each compound actually does, how the human evidence stacks up as of 2026, and where the real safety trade-offs lie — including the January 2026 head-to-head human trial that finally pitted NR against NMN directly, and the FDA's 2025 reversal on NMN's legal status. Quick Answer NAD+ is the coenzyme your cells actually need for energy production and DNA repair, and it can't be taken as an oral supplement because it's too large a molecule to survive digestion intact. NR, NMN,...
Read more

10 Best Vitamin & Longevity Supplement Brands on Amazon (2026 Doctor-Reviewed Guide)

By Dr Frank Yap, MD
Image
Medical & Science Review: Updated by the One Day MD Editorial Team | Evidence Level: High (Clinical trials, cGMP Standards, Advanced Liposomal Tech, & Third-Party Lab Testing). Navigating dietary supplements on Amazon requires cutting through marketing hype to find medical-grade purity and verified cellular absorption. While generic store brands often rely on synthetic, low-yield compounds (like cyanocobalamin or inorganic oxide minerals), leading functional medicine, liposomal delivery, and longevity science brands prioritize bioavailable forms that bypass GI degradation. In this guide, we review the 10 best US supplement and vitamin brands on Amazon —evaluating practitioner-grade multivitamins, nano-liposomal nutrient technology, and targeted longevity molecules. 🔬 Beyond Standard Multivitamins: The 3 Pillars of Superior Supplementation When selecting clinical-grade supplements on Amazon, pay close attention to three key performa...
Read more

Testosterone, Men's Health & Healthy Aging: Low T, Testosterone Replacement and the Science of Anti-Aging

By Dr Frank Yap, MD
Image
Testosterone is one of the most important hormones in male health. It influences sexual function, muscle mass, bone health, red-blood-cell production, body composition and aspects of mood and energy. Testosterone levels also tend to decline as men age, creating growing interest in testosterone testing, testosterone replacement therapy (TRT), men's health optimization and longevity. Interest in testosterone treatment is also increasing again. New 2026 data from Epic Research show that testosterone prescribing rates in the United States have begun rising again after nearly a decade of decline. The trend is important because it suggests a renewed clinical and consumer focus on testosterone, men's health and hormonal aging—but a rise in prescribing does not itself prove that testosterone therapy is appropriate for every man. The central question remains: Does a man have clinically meaningful testosterone deficiency, what is causing it, and is testosterone replacement lik...
Read more

How Many Years Can a Healthy Lifestyle Add to Your Life? The Evidence on Diet, Exercise, Supplements & Anti-Aging Drugs (2026)

By
Image
Short answer: A healthy lifestyle may add years to life—and potentially a decade or more in some populations—but there is no scientifically valid number that applies to everyone. The strongest evidence suggests that the biggest gains come from a combination of not smoking, regular physical activity, a high-quality diet, maintaining a healthy body weight, and controlling major cardiovascular and metabolic risk factors . One influential U.S. analysis estimated that people who followed five low-risk lifestyle factors at age 50 had a projected life expectancy about 14 years longer for women and 12 years longer for men than people following none of those factors. However, this was a prospective observational analysis combined with life-table modelling—not a randomized trial proving that each person will live exactly 12–14 years longer. That distinction matters. It is tempting to interpret longevity studies as if they were a prescription for an extra number of years: exercise gi...
Read more

Butyrate: The Ultimate Guide to Supplements, Foods & Gut Health (2026)

By Dr Frank Yap, MD
Image
Butyrate is a powerhouse short-chain fatty acid (SCFA) essential for gut integrity, immune balance, metabolism, and even brain health. This pillar page will guide readers through everything they need to know about butyrate — from supplements to foods, to strategies for boosting production naturally. Table of Contents What Is Butyrate? Best Butyrate Supplements Sodium & Calcium Butyrate Tributyrin Supplements Prebiotic + Butyrate Blends Clostridium butyricum Probiotics Best Foods That Increase Butyrate Naturally Resistant Starch Foods Soluble & Fermentable Fiber Polyphenol-Rich Foods Foods That Contain Butyrate Directly How to Maximise Butyrate Production Supplements vs Foods: Which Is Better? Who Benefits Most from Butyrate? Key Takeaways What Is Butyrate? Butyrate (butyric acid) is a short-chain fatty acid produced when beneficial gut bacteria ferment fiber and resistant starch. According to research on PubMed, butyrate is the primary energy source for colonocytes, the cells ...
Read more

Procyanidin C1 (PCC1): Senolytic Effects, Anti-Aging Research & 2026 Evidence

By Dr Frank Yap, MD
Image
OneDayMD • Longevity • Senotherapeutics Procyanidin C1 (PCC1) is a grape-seed-derived polyphenol that has attracted major interest in longevity research because of its reported senolytic and senomorphic effects . Laboratory and animal studies suggest that PCC1 can alter senescent-cell behavior and, under certain experimental conditions, selectively eliminate senescent cells. 2026 Evidence Update: The landmark 2021 PCC1 study published in Nature Metabolism has received an Editorial Expression of Concern . The journal reported concerns involving one figure and the availability of underlying raw data. This does not establish that PCC1 is ineffective, but it means that some of the original findings — particularly lifespan-related claims — should be interpreted cautiously pending independent confirmation. Bottom line: PCC1 is a promising experimental senotherapeutic compound, ...
Read more

Outsmarting Knee Arthritis: Why Common Surgeries Backfire & How to Heal Joints Naturally

By Dr Frank Yap, MD
Image
Over 53 million Americans live with arthritis—a staggering number projected to soar to 78.4 million by 2040 according to the Centers for Disease Control and Prevention (CDC). For decades, the conventional medical response to chronic knee pain and meniscus wear has been quick-fix surgical interventions like arthroscopic partial meniscectomy. However, emerging 10-year clinical trials and insights from leading sports medicine surgeons reveal a surprising truth: many of these common surgeries do more harm than good. If you are experiencing knee stiffness, cartilage degradation, or persistent joint pain, you don't have to choose between invasive surgery and lifelong disability. By combining the latest orthopedic science, targeted "3D" movement, low-load muscle strengthening, and anti-inflammatory nutrition, you can protect your joint health and outsmart arthritis naturally. 📌 Executive Summary & Key Discoveries The Surgery Myth: A 10-year randomize...
Read more

Preventing Alzheimer’s Disease and Dementia in 2026: An Evidence-Based Review of Lifestyle, Supplements, Biomarkers, and Metabolic Health

By Dr Frank Yap, MD
Image
Updated: August 2026 | Article type: Evidence review | Original publication: 2022; substantially revised and rebuilt in 2026 Clinical focus: Alzheimer’s disease prevention, dementia risk reduction, multidomain lifestyle intervention, p-tau217 blood biomarkers, metabolic health, GLP-1 receptor agonists, SGLT2 inhibitors, and dietary supplements. Abstract Background: Alzheimer’s disease (AD) is a multifactorial neurodegenerative disorder in which age, genetics, vascular disease, metabolic dysfunction, hearing loss, physical inactivity, depression, social isolation and other modifiable factors contribute to risk. The prevention landscape has changed substantially since this article was first published in 2022. Objective: To update the evidence concerning practical strategies for reducing dementia risk, with particular attention to multidomain lifestyle interventions, nutritional adequacy, dietary supplements, blood-based biomarkers and emerging metabolic therapies. Metho...
Read more

SELECT, STEP, SURPASS & FLOW: What the Landmark Semaglutide and Tirzepatide Trials Actually Prove (2026)

By
Image
By Dr. Frank Yap, MD  |  Medically reviewed by One Day MD Review Team  |  Last updated: August 2026 Quick Answer SELECT showed that semaglutide 2.4 mg cuts major cardiovascular events by 20% in people with overweight/obesity and existing heart disease who do not have diabetes. The STEP program (STEP 1–5, STEP 8, and the newer STEP UP trials) established semaglutide's weight-loss profile, with losses ranging from roughly 10% to over 20% of body weight depending on dose, population, and duration. The SURPASS program showed that tirzepatide — a dual GIP/GLP-1 agonist — produces larger HbA1c and weight reductions than semaglutide in type 2 diabetes, and the newly published SURPASS-CVOT (December 2025) confirmed tirzepatide is at least as cardioprotective as dulaglutide. FLOW showed semaglutide cuts major kidney disease events by 24% in people with type 2 diabetes and chronic kidney disease, which led the FDA to approve a dedicated kidney-protection indic...
Read more